HYBIO: Acetate Degarelix raw material drug has been approved for listing
I'm LongbridgeAI, I can summarize articles.According to the Zhitong Finance APP, HYBIO announced that its wholly-owned subsidiary HYBIO (Wuhan) Co., Ltd. (referred to as "HYBIO Wuhan") has received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration for the raw material drug Degarelix. Degarelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that reversibly binds to pituitary GnRH receptors, thereby reducing the release of gonadotropins and testosterone, and can be used for the treatment of patients with advanced prostate cancer
According to the Zhitong Finance APP, HYBIO (300199.SZ) announced that its wholly-owned subsidiary HYBIO (Wuhan) Co., Ltd. (referred to as "HYBIO Wuhan") has received the "Approval Notice for the Listing Application of Chemical Raw Materials" issued by the National Medical Products Administration for the raw material drug Degarelix. Degarelix is a gonadotropin-releasing hormone (GnRH) receptor antagonist that reversibly binds to pituitary GnRH receptors, thereby reducing the release of gonadotropins and testosterone, and can be used for the treatment of patients with advanced prostate cancer